Hyoung Jun Koh

Yonsei University Hospital, Sŏul, Seoul, South Korea

Are you Hyoung Jun Koh?

Claim your profile

Publications (110)248.45 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the accuracy of postoperative refractive outcomes of combined phacovitrectomy for epiretinal membrane (ERM) in comparison to cataract surgery alone. Thirty-nine eyes that underwent combined phacovitrectomy with intraocular lens (IOL) implantation for cataract and ERM (combined surgery group) and 39 eyes that received phacoemulsification for cataract (control group) were analyzed, retrospectively. The predicted preoperative refractive aim was compared with the results of postoperative refraction. In the combined surgery group, refractive prediction error by A-scan and IOLMaster were -0.305±0.717 diopters (D) and -0.356±0.639 D, respectively, compared to 0.215±0.541 and 0.077±0.529 in the control group, showing significantly more myopic change compared to the control group (p=0.001 and p=0.002, respectively). Within each group, there was no statistically significant difference in refractive prediction error between A-scan and IOLMaster (all p>0.05). IOL power calculation using adjusted A-scan measurement of axial length based on the macular thickness of the normal contralateral eye still resulted in significant postoperative refractive error (all p<0.05). Postoperative refraction calculated with adjusted axial length based on actual postoperative central foveal thickness change showed the closest value to the actual postoperative achieved refraction (p=0.599). Combined phacovitrectomy for ERM resulted in significantly more myopic shift of postoperative refraction, compared to the cataract surgery alone, for both A-scan and IOLMaster. To improve the accuracy of IOL power estimation in eyes with cataract and ERM, sequential surgery for ERM and cataract may need to be considered.
    Yonsei medical journal 05/2015; 56(3):805-11. DOI:10.3349/ymj.2015.56.3.805 · 1.26 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the causes of acute spontaneous submacular hemorrhage with indocyanine green angiography (ICGA). Retrospective observation case series. A total of 51 eyes from 51 patients with newly developed spontaneous submacular hemorrhage were enrolled. Best-corrected visual acuity (BCVA), fundus photography, fluorescein angiography, spectral domain optical coherence tomography (OCT), and ICGA at baseline were analyzed. The extent of hemorrhage using fundus photography, height of hemorrhage, and central foveal thickness measured by OCT was analyzed to compare the diagnostic and nondiagnostic groups. The mean logarithm of the minimum angle of resolution (logMAR) BCVA at presentation was 1.21 ± 0.74 (Snellen equivalent, 20/324); the mean follow-up period was 23.9 ± 23.9 months. The cause of submacular hemorrhage was diagnosed in 43 of 51 eyes (84.3%) based on ICGA at presentation. The initial diagnoses were correct in 93% of eyes. In 3 cases, the initial diagnosis of age-related macular degeneration (AMD) was changed to polypoidal choroidal vasculopathy (PCV) based on follow-up ICGA. The central foveal thickness was significantly greater in the nondiagnostic group (1,102.4 vs. 666.7 μm, respectively; p = 0.008). The most common cause of submacular hemorrhage was neovascular AMD (52.9%), followed by PCV (37.3%), macroaneurysm (5.9%), and lacquer crack (3.9%). The mean final visual acuity was generally worse in patients with submacular hemorrhage with typical AMD (visual acuity 20/618) or PCV (visual acuity 20/240) compared to that in patients with retinal macroaneurysm (visual acuity 20/100) or lacquer crack (visual acuity 20/72). ICGA at initial presentation helps identify causes of submacular hemorrhage, allowing differential treatment approaches that may improve outcomes and safety. © 2015 S. Karger AG, Basel.
    Ophthalmologica 03/2015; DOI:10.1159/000380830 · 1.87 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To compare the functional and anatomical outcomes of intravitreal bevacizumab (IVB) with those of dexamethasone implant injection (IVD) for macular oedema associated with branch retinal vein occlusion (BRVO). Seventy-two patients with centre-involving macular oedema secondary to BRVO were retrospectively enrolled in the study; these patients were treated with either 1.25 mg IVB (44 eyes; mean injections: 2.92±1.38) pro re nata (PRN) by follow-up monthly or 700 µg IVD (28 eyes; mean injections: 1.71±0.47) given at 6-month intervals PRN and were followed for at least 12 months. Main outcome measures were changes in best-corrected visual acuity (BCVA) and central foveal thickness (CFT). There was no statistically significant difference of mean change of the logarithm of the minimum angle of resolution BCVA between IVB and IVD groups at monthly visits, up to 12 months (all p>0.05); however, there was a trend towards greater BCVA gain in the IVB group than in the IVD group at 6 months (p=0.053). Additionally, 52.6% in the IVB group and 50% in the IVD group gained two or more lines of Snellen visual acuity at 12 months (p=0.85). The mean CFT decreased by 160 µm for the IVB group and by 140.7 µm for the IVD group at 12 months. Both the IVB group and the IVD group achieved statistically similar improvement of CFT at monthly visits, up to 5 months (all p>0.05); however, the CFT began to deteriorate after 5 months in the IVD group, and at 6 months, improvement in the IVB group was significantly greater than that in the IVD group (p=0.007). After a second IVD injection at 6 months, the IVD group showed significant improvement of CFT, and there was no significant difference of CFT change between the IVB and IVD groups until 12 months. For macular oedema secondary to BRVO, IVB administered PRN monthly and IVD administered PRN at 6-month intervals, yielded functionally and anatomically comparable outcomes at 12 months. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: To report short-term surgical outcomes of single-stage simultaneous rescue and sutureless intrascleral fixation of dislocated intraocular lens (IOLs). Methods: Sixteen eyes of 16 patients who underwent simultaneous rescue and intrascleral fixation of dislocated 3-piece IOLs were retrospectively evaluated. Partial thickness limbal-based scleral flaps (2.0 x 2.0 mm) were created, and a 22-gauge round needle was used to create a sclerotomy at 1.5 mm from the limbus under the previously created scleral flap, and a 23-gauge trans pars plana vitrectomy was performed. Bimanual maneuvers using two 23-gauge end-grasping forceps under chandelier illumination and a wide-angle viewing system enabled 1 step rescue of IOLs from the posterior vitreous cavity with 1 hand and simultaneous haptic externalization through sclerotomy with the other hand. An externalized haptic was placed into the 3-mm intrascleral tunnel created using a bent 26-gauge needle. Fibrin glue was used to fixate haptics and close the scleral flaps. Results: Intraocular lenses were successfully rescued and sclera-fixated through intrascleral tunnels in all 16 eyes (mean age, 56.56 +/- 19.89 years). The mean preoperative logarithm of the minimum angle of resolution best-corrected visual acuity was 0.92 +/- 0.68, and this significantly improved at 6 months to 0.289 +/- 0.36 (P = 0.003). During the follow-up period (10.1 +/- 3.21 months), no significant change of endothelial cell count or central foveal thickness was noted postoperatively (P = 0.203 and P = 0.979, respectively). There were no significant postoperative complications such as IOL dislocation, IOL decentration, retinal detachment, endophthalmitis, or postoperative hypotony. Conclusion: Simultaneous rescue and sutureless intrascleral haptic fixation of dislocated 3-piece IOLs using bimanual maneuvers is an effective, safe, and minimally invasive surgical method to rescue and fixate the dislocated IOL without further explant.
    Retina 01/2015; DOI:10.1097/IAE.0000000000000484 · 3.18 Impact Factor
  • Source
    Korean Journal of Ophthalmology 10/2014; 28(5):424-426. DOI:10.3341/kjo.2014.28.5.424
  • Hae Min Kang, Hyoung Jun Koh, Sung Chul Lee
    [Show abstract] [Hide abstract]
    ABSTRACT: To assess the visual outcome and prognostic factors after surgery for a secondary epiretinal membrane (ERM) due to branch retinal vein occlusion (BRVO).
    Albrecht von Graæes Archiv für Ophthalmologie 07/2014; DOI:10.1007/s00417-014-2731-2 · 2.33 Impact Factor
  • Min Kim, Sung Soo Kim, Hyoung Jun Koh, Sung Chul Lee
    [Show abstract] [Hide abstract]
    ABSTRACT: To investigate choroidal thickness (CT) in healthy Korean subjects measured by enhanced depth imaging optical coherence tomography and its association with age, axial length, and refractive error. Choroidal scans using enhanced depth imaging optical coherence tomography in each eye of 286 healthy eyes were obtained at the macula. Choroidal thickness was measured at the fovea. Two separate line scans were obtained (one horizontal and one vertical). The mean (±SD) age was 40.18 (±17.89) years (range, 13 to 75 years). The mean (±SD) subfoveal CT was 307.26 (±95.18) μm. Multivariable linear regression suggested that age and refractive error were the most significant factors associated with subfoveal CT (all p < 0.0001) with an adjusted R = 0.181. In subjects younger than 60 years, refractive error or axial length and age retained statistically significant correlation with subfoveal CT, whereas such a relationship was lost in subjects older than 60 years. The mean subfoveal CT measurement showed the most significant positive correlation with refractive error and the most significant negative correlation with age. For patients younger than 60 years, there was a significant correlation of subfoveal CT with age and refractive error or axial length, whereas such significant association was not observed in subjects older than 60 years.
    Optometry and vision science: official publication of the American Academy of Optometry 04/2014; DOI:10.1097/OPX.0000000000000229 · 2.04 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This case describes the reversal of early central retinal vein occlusion (CRVO) with disc swelling after intravitreal dexamethasone implant (Ozurdex) injection. A 44-year-old female presented with sudden-onset intermittent blurred vision in her left eye. Fundus examination revealed multiple retinal hemorrhages without macular edema (ME). Two weeks later, an increased number of retinal hemorrhages with severe disc swelling were noted with still no sign of ME. An intravitreal dexamethasone implant was injected. Five days later, there were improvements in disc swelling and retinal hemorrhage. One month later, her subjective visual symptoms were completely improved, and fundus examination revealed marked improvement along with almost complete resolution of disc swelling. Intravitreal dexamethasone implant injection may potentially change the natural course of CRVO progression and its various subsequent complications.
    Korean Journal of Ophthalmology 04/2014; 28(2):192-3. DOI:10.3341/kjo.2014.28.2.192
  • Dong Hyun Lee, Sung Soo Kim, Min Kim, Hyoung Jun Koh
    [Show abstract] [Hide abstract]
    ABSTRACT: To investigate identifiable peripheral retinal lesions in patients with myopia or high myopia and to evaluate the usefulness of ultra-widefield scanning laser ophthalmoscope in retina clinic settings.
    Journal of the Korean Ophthalmological Society 01/2014; 55(12):1814. DOI:10.3341/jkos.2014.55.12.1814
  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the characteristics of rhegmatogenous retinal detachment (RD) in patients with previous laser in-situ keratomileusis (LASIK) and compared them to RD in patients with previous laser assisted sub-epithelial keratomileusis (LASEK) and myopic patients with no previous refractive surgery. Retrospective, comparative case series METHODS: Among 106 eyes of 106 patients, RD patients with previous refractive surgery included 21 eyes with LASIK and 13 eyes with LASEK. 72 myopic patients with refractive errors of -3.0 diopters or less were grouped as the R (-) group. Characteristics of RD included distribution of RD and associated retinal breaks, location and number of retinal breaks, presence of lattice degeneration, and axial lengths. The mean interval between refractive surgery and the onset of rhegmatogenous RD was 63.7±43.5 months, occurring across a broad spectrum of time interval. There were no significant differences among LASIK group, LASEK group, and R (-) group in axial length (26.8 mm vs. 26.4 mm vs. 26.9 mm, respectively), mean number of retinal holes/tears, (2.1/1.5, 0.9/1.4, 1.5/1.6, respectively) and the presence of lattice degeneration(52.4%vs. 46.2% vs. 43.1%, respectively). Distribution of RD and associated retinal breaks were also not significant different, as retinal holes and tears were more prevalent in the temporal quadrants, and inferotemporal quadrants was the most commonly detached area in both LASEK/LASIK group and R (-) group. Myopia is a well-known risk factor for rhegmatogenous RD and may contribute more to the development of RD in myopic patients after refractive surgery, rather than refractive surgery itself.
    American Journal of Ophthalmology 12/2013; 157(3). DOI:10.1016/j.ajo.2013.12.004 · 4.02 Impact Factor
  • Hae Min Kang, Hyoung Jun Koh
    [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the prevalence of polypoidal choroidal vasculopathy (PCV) in patients with myopic choroidal neovascularization (CNV) using indocyanine green angiography (ICGA). Retrospective cross-sectional study. A total of 297 eyes (255 patients) who presented with treatment-naive myopic CNV between January 2005 and December 2011 at Yonsei University Medical Center in Seoul, South Korea, were reviewed. Fluorescein angiography (FA) images obtained from the patients were analyzed to detect CNV presence and classify disease type. ICGA images were reviewed to detect polypoidal lesions. The main outcome measure was the prevalence of polypoidal lesions in patients with myopic CNV. All 297 eyes with myopic CNV were type 2 CNV, and mean age at diagnosis was 47.32 ± 14.69 years. The mean refractive error was -11.95 ± 5.88 diopters, and the mean axial length was 29.39 ± 2.02 mm in the affected eyes. Among the myopic CNV eyes, 141 eyes (118 patients) were older than 50 years of age (mean 60.48 ± 7.34 years). No eyes with myopic CNV showed polypoidal lesions on ICGA at initial presentation. After treatments for myopic CNV, 243 eyes (206 patients) completed at least 12 months of follow-up, and 86 eyes (35.4%) showed at least one recurrence of CNV during follow-up. The follow-up imaging studies, FA, and ICGA, showed no polypoidal lesions associated with recurred myopic CNV. ICGA analysis demonstrated no polypoidal component in myopic eyes with CNV.
    American Journal of Ophthalmology 12/2013; 157(2). DOI:10.1016/j.ajo.2013.09.018 · 4.02 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the long-term visual outcome after combination therapy of photodynamic therapy (PDT) with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy (PCV). Retrospective, observational study. The medical records of 34 eyes (34 patients) with naive PCV who were treated with combination therapy were analyzed. All patients completed at least 3 years of follow-up. All clinical data, including age, best-corrected visual acuity (BCVA, logMAR; logarithm of the minimum angle resolution), imaging data of fluorescein angiography, indocyanine green angiography, and optical coherence tomography, were investigated. During a mean follow-up period of 46.82 ± 5.22 months, a mean of 1.44 ± 0.71 times of PDT and 9.18 ± 6.61 intravitreal bevacizumab injections were performed. During follow-up, 21 eyes (61.8%) showed at least one recurrence. Mean BCVA was 0.59 ± 0.35 logMAR (20/77 Snellen equivalent) at baseline, and 0.39 ± 0.34 logMAR (20/49 Snellen equivalent) at 3 years (P=.004). At 3 years, 14 patients (41.2%) gained 0.3 logMAR or more BCVA, and 4 patients (11.8%) lost 0.3 logMAR or more BCVA than baseline. Baseline polyp size (B=.551; P=.005) and location of polyps (B= -.400; P=.033) were significantly correlated with long-term visual outcome after combination therapy for PCV. Combination therapy of PDT with intravitreal bevacizumab injections showed favorable visual outcomes, and significant visual improvement was maintained in PCV patients. A total of 88.2% of patients avoided visual loss at 3 years after treatments. Largest polyp size at baseline and location of polypoidal lesions were prognostic factors for long-term visual outcomes in these patients.
    American Journal of Ophthalmology 11/2013; 157(3). DOI:10.1016/j.ajo.2013.11.015 · 4.02 Impact Factor
  • Acta ophthalmologica 10/2013; 92(1). DOI:10.1111/aos.12285 · 2.51 Impact Factor
  • Hae Min Kang, Hyoung Jun Koh
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: To compare treatment outcomes of photodynamic therapy (PDT), anti-vascular endothelial growth factor (VEGF) therapy and PDT combined with anti-VEGF therapy for polypoidal choroidal vasculopathy (PCV). Procedures: A total of 62 eyes of 62 patients who had completed at least 2 years of follow-up were retrospectively reviewed; 19 eyes received PDT only, 23 had anti-VEGF therapy only and 20 underwent combination therapy. Best-corrected visual acuity at baseline and each follow-up visit was investigated as a primary outcome measure. Results: At year 2, the PDT and combination groups maintained significant visual improvement (p = 0.041 and p = 0.021), whereas the anti-VEGF group failed to do so (p = 0.673) when compared with the baseline. The combination group showed better visual outcome during follow-up, and significantly better visual outcome than the PDT group (p = 0.038) and the anti-VEGF group (p = 0.012) at year 2. Conclusions: Combination therapy leads to significantly better visual outcome than PDT and anti-VEGF monotherapy and is therefore a superior method for treating PCV, with a favorable visual outcome. © 2013 S. Karger AG, Basel.
    Ophthalmologica 10/2013; 231(2). DOI:10.1159/000354546 · 1.87 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: To evaluate the change in choroidal thickness (CT) between active and quiescent phases of Behcet's posterior uveitis and compare this to the normal population using enhanced depth imaging optical coherence tomography (EDI-OCT). Methods: Thirty eyes from 30 patients with Behcet's posterior uveitis (mean age, 47.03 ± 11.01 years) were retrospectively enrolled in the study. Their subfoveal CT was measured using EDI-OCT in the active and quiescent phases of Behcet's uveitis, and compared with the age, sex, and spherical equivalent-matched normal population. Changes in retinal vascular leakage on fluorescein angiography (FA) were correlated with the changes in CT. Results: Mean subfoveal CT in the acute phase of Behcet uveitis was significantly greater than that in the quiescent phase (398.77 ± 155.59 μm vs 356.72 ± 141.09 μm; p=0.004). CT in the quiescent phase was also significantly greater than that of the normal population (259.96 ± 65.16 μm; p<0.0001). There was a statistically significant association between the change in subfoveal CT and the change in vascular leakage revealed by FA. (ρ = 0.381, p=0.046). Subfoveal CT in the uninvolved fellow eyes of patients with unilateral Behcet's uveitis was also evaluated and it was significantly greater than that of the normal population. (n=13 eyes; p=0.001) Conclusions: This study found choroidal thickening during the active phase of Behcet's posterior uveitis. CT during the quiescent phase was also significantly greater than in normal eyes. The degree of reduction in choroidal thickening was significantly correlated with improvement in retinal vascular leakage as revealed by FA.
    Investigative ophthalmology & visual science 07/2013; 54(9). DOI:10.1167/iovs.13-12231 · 3.66 Impact Factor
  • Hae Min Kang, Hyoung Jun Koh
    [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate long-term visual outcome and investigate the prognostic factors after anti-vascular endothelial growth factor (VEGF) therapy for polypoidal choroidal vasculopathy (PCV). Retrospective study. Analyses were done among 36 eyes (36 patients) with naïve PCV that were treated with intravitreal ranibizumab injections and completed at least 3-year follow-up. All clinical data, including baseline characteristics; imaging data from fluorescein angiography, indocyanine green angiography, and optical coherence tomography; presence of recurrence; and best-corrected visual acuity (BCVA) were investigated. During mean follow-up of 42.58 ± 12.59 months, mean numbers of anti-VEGF injection were 11.45 ± 7.81. Twenty-four eyes (66.7%) showed at least 1 recurrence during follow-up. Mean baseline BCVA was 0.68 ± 0.43 logMAR (20/95 Snellen equivalent), and 0.78 ± 0.53 logMAR (20/120 Snellen equivalent) at 36 months (P = .307). Mean BCVA was significantly improved at 1 month (P = .018), and improvement was maintained until 12 months (P = .044), then deteriorated. Among baseline characteristics, greatest lesion diameter (B = 0.219, P = .001) and pigment epithelial detachment (B = 0.362, P = .025) were significantly correlated with long-term visual outcome. Recurrence during follow-up (B = 0.371, P = .024) was also significantly correlated with long-term visual outcome. Significant visual improvement by anti-VEGF therapy was maintained during the first year of initial treatment; however, vision then deteriorated during long-term follow-up. Smaller lesion size, absence of pigment epithelial detachment at baseline, and no recurrence during follow-up were significantly correlated with better long-term visual outcome.
    American Journal of Ophthalmology 07/2013; DOI:10.1016/j.ajo.2013.05.038 · 4.02 Impact Factor
  • Hae Min Kang, Hyoung Jun Koh
    [Show abstract] [Hide abstract]
    ABSTRACT: PURPOSE:: To investigate factors associated with long-term recurrence of myopic choroidal neovascularization (CNV) after treatment with photodynamic therapy (PDT) and/or intravitreal antivascular endothelial growth factor injections. METHODS:: Seventy-six eyes with myopic CNV completed at least a 48-month follow-up after treatments. The baseline characteristics of the eyes were compared, including age, gender, refractive errors, axial lengths, location of CNV, lacquer cracks, chorioretinal atrophy, dark rim, great linear dimension, and prior PDT. RESULTS:: During mean follow-up of 71.21 ± 26.43 months, 35 eyes (46.1%) experienced at least 1 recurrence. Mean interval between initial treatment and first recurrence was 24.15 ± 18.10 months. Presence of lacquer crack (P = 0.022, χ test), absence of dark rim (P = 0.031, χ test), and prior PDT (P = 0.041, χ test) were significantly different between the eyes with and without recurrence. Among baseline characteristics, presence of lacquer crack (β = 1.272, P = 0.012) prior PDT (β = 1.607, P = 0.027), and absence of dark rim (β = -0.758, P = 0.020) were significantly associated with the recurrence of myopic CNV after treatment by multiple logistic regression. CONCLUSION:: Long-term follow-up revealed recurrence of myopic CNV in 46.1% of the patients after treatment. Presence of lacquer cracks, prior PDT, and absence of dark rim were risk factors for recurrence of myopic CNV.
    Retina (Philadelphia, Pa.) 04/2013; DOI:10.1097/IAE.0b013e318285cc24 · 3.18 Impact Factor
  • Source
    Hae Min Kang, Hyoung Jun Koh, Eun Jee Chung
    [Show abstract] [Hide abstract]
    ABSTRACT: A 5-year-old girl was diagnosed with neurofibromatosis type 2 (NF-2) due to multiple neurofibromas, cafe-au-lait spots, and schwannomas of the brain. During ophthalmologic evaluation, a posterior subcapsular cataract and a gray-green colored subretinal lesion were found in right eye. Fluorescein angiography (FA) revealed a combined hamartoma of the retina and retinal pigment epithelium (CHRRPE). At age 9, she underwent cataract surgery. At this time FA and spectral-domain optical coherence tomography (SD-OCT) were taken. The SD-OCT showed an elevated hyperreflective mass in the retina with prominent attenuation of the inner and outer retina, but minimal attenuation in the photoreceptor layers. The underlying retina appeared to be disorganized and thick (791 µm). This is the first case report of SD-OCT imaging of a CHRRPE associated with NF-2 in a pediatric patient. By using SD-OCT in this patient, we could obtain detailed tumor characteristics, and SD-OCT may be helpful in the diagnosis and management of CHRRPE.
    Korean Journal of Ophthalmology 02/2013; 27(1):68-71. DOI:10.3341/kjo.2013.27.1.68
  • Hae Min Kang, Hyoung Jun Koh
    [Show abstract] [Hide abstract]
    ABSTRACT: PURPOSE: To compare visual outcomes after intravitreal anti-vascular endothelial growth factor (VEGF) injection or photodynamic therapy (PDT) for idiopathic choroidal neovascularization (CNV). DESIGN: Retrospective study. METHODS: Among 29 eyes (28 patients), 15 eyes (15 patients) received anti-VEGF therapy and 14 eyes (13 patients) received PDT. Best-corrected visual acuity (BCVA, logMAR [logarithm of minimal angle of resolution]) at baseline and 1, 3, 6, 12, and 24 months after initial treatment were compared. The eyes were classified by BCVA changes: improved (improvement ≥0.3 logMAR), decreased (deterioration ≥0.3 logMAR), and stable. RESULTS: Mean BCVA was 0.56 ± 0.38 logMAR (20/72 in Snellen equivalent) in the PDT group and 0.44 ± 0.59 logMAR (20/55 in Snellen equivalent) in the anti-VEGF group at baseline (P = .104, Mann-Whitney U test). The anti-VEGF group showed significantly better mean BCVA at each follow-up visit when compared with that of PDT (P = .004 at 1 month, P = .002 at 3 months, P = .037 at 6 months, P = .031 at 12 months, and P = .049 at 24 months; Mann-Whitney U test, respectively). When compared with the baseline, mean BCVA at each follow-up visit was better in the anti-VEGF group (P = .196 at 1 month, P = .007 at 3 months, P = .046 at 6 months, P = .046 at 12 months, and P = .049 at 24 months; Wilcoxon signed rank test, respectively), whereas BCVA in the PDT group was not. At 24 months, all eyes (100.0%) treated with anti-VEGF showed stable or improved BCVA, whereas 3 eyes (21.3%) showed visual deterioration after PDT. CONCLUSIONS: Anti-VEGF therapy was superior to PDT for idiopathic CNV, and superior efficacy was sustained until 24 months.
    American Journal of Ophthalmology 12/2012; DOI:10.1016/j.ajo.2012.10.010 · 4.02 Impact Factor
  • Hae Min Kang, Yong Min Kim, Hyoung Jun Koh
    [Show abstract] [Hide abstract]
    ABSTRACT: PURPOSE: To evaluate the 5-year efficacy of photodynamic therapy (PDT) in patients with polypoidal choroidal vasculopathy (PCV). DESIGN: Retrospective study. METHODS: Forty-two eyes of 36 patients with PCV followed up for at least 60 months after PDT were reviewed. All eyes were primarily treated with PDT. Main outcome measure was best-corrected visual acuity (BCVA; logMAR [logarithm of minimal angle of resolution]) at baseline and at each follow-up visit. We also classified the eyes into 3 groups: improved (improvement ≥0.3 logMAR), decreased (deterioration ≥0.3 logMAR), and stable. RESULTS: During the mean follow-up duration, 73.64 ± 13.47 months, the mean number of PDT was 2.21 ± 1.62 treatments. Recurrence was noted in 33 eyes (78.6%) during follow-up. The mean baseline BCVA was 0.78 ± 0.48 logMAR (20/120 Snellen equivalent), and the final BCVA at 60 months was 0.67 ± 0.52 logMAR (20/93 Snellen equivalent) (P = .050, paired t test). On the final evaluation at 60 months, the mean BCVA was improved in 14 eyes (33.3%), stable in 23 eyes (54.7%), and decreased in 5 eyes (11.9%). CONCLUSION: At 60 months after initial PDT, 88.1% of PCV patients showed stable or improved BCVA after PDT. Despite a high recurrence rate, PDT remained effective for 5 years, and represents a good therapeutic approach to PCV.
    American Journal of Ophthalmology 12/2012; 155(3). DOI:10.1016/j.ajo.2012.09.020 · 4.02 Impact Factor

Publication Stats

1k Citations
248.45 Total Impact Points


  • 2000–2015
    • Yonsei University Hospital
      • Department of Internal Medicine
      Sŏul, Seoul, South Korea
  • 2001–2013
    • Yonsei University
      • The Institute of Vision Research
      Sŏul, Seoul, South Korea
  • 2006–2009
    • University of California, San Diego
      • Department of Ophthalmology
      San Diego, CA, United States
  • 2008
    • National Health Insurance Corporation Ilsan Hospital
      Sŏul, Seoul, South Korea
  • 2007
    • Inje University
      • College of Medicine
      Kimhae, South Gyeongsang, South Korea
  • 2004
    • National University (California)
      San Diego, California, United States